-
Biggest News in Early-Stage Lung Cancer Research from WCLC 2025
Read time: 2 minutes.
The annual World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer, is the largest global meeting dedicated to lung cancer...
IN THE SPOTLIGHT
-
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
Read time: 3 minutes. For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are... -
6 Tips for Managing Scanxiety
Read time: 4 minutes. Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as... -
First Oral Targeted Therapy Approved for Advanced HER2+ NSCLC
On August 8, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) to treat patients with unresectable or metastatic non... -
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming... -
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue... -
New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non... -
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and... -
Weekly Virtual Meetup
For patients/survivors - Join us every Tuesday at 12 pm ET for this general meetup for anyone impacted by lung cancer. After registering, you will receive a confirmation email...
Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual...
Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual...
Perioperative Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest
Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis
Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis
Integrated machine learning survival framework for consensus modeling in a large multicenter cohort of NSCLC resistant to aumolertinib
Integrated machine learning survival framework for consensus modeling in a large multicenter cohort of NSCLC resistant to aumolertinib
Double-Dose Furmonertinib Shows Efficacy in Treating NSCLC with EGFR Exon 20 Insertions
EIK1001 Plus Pembrolizumab/Chemo ORR 64% in 1L Stage IV NSCLC
Sacituzumab Tirumotecan in EGFR-Mutated Advanced NSCLC
Clinical Outcomes of Later‐Generation EGFR‐TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real‐World Study
Clinical Outcomes of Later‐Generation EGFR‐TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real‐World Study
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
Read time: 3 minutes. For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to optimize existing therapies and are exploring entirely new treatment approaches. At the 2025 World Conference on Lung Cancer (WCLC), several studies highlighted progress in treating newly diagnosed individuals as well as those who need new options after standard therapies stop working. …
Biggest News in Early-Stage Lung Cancer Research from WCLC 2025
Biggest News in Early-Stage Lung Cancer Research from WCLC 2025
Read time: 2 minutes. The annual World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer, is the largest global meeting dedicated to lung cancer research. WCLC 2025 showcased several important studies that focused on treating resectable (surgically removable) non-small cell lung cancer (NSCLC). Several studies showed that giving patients immunotherapy (treatments that leverage the body’s natural immune system to fight cancer)…
6 Tips for Managing Scanxiety
6 Tips for Managing Scanxiety
Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…
First Oral Targeted Therapy Approved for Advanced HER2+ NSCLC
First Oral Targeted Therapy Approved for Advanced HER2+ NSCLC
On August 8, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) to treat patients with unresectable or metastatic non-small cell lung cancer (NSCLC) with mutations in the HER2 gene. This approval is for patients who have been previously treated with a systemic therapy (such as chemotherapy). Mutations in the HER2 gene (also called the ERBB2 gene) are responsible for approximately 2-3% of nonsquamous NSCLCs. These mutations…
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
New Treatment Approved for NSCLC with High Level of c-Met Protein
New Treatment Approved for NSCLC with High Level of c-Met Protein
On May 14, 2025, the US Food and Drug Administration (FDA) announced the approval of telisotuzumab vedotin-tllv (EMRELIS™) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with high levels of c-Met protein who have been previously treated with a systemic therapy, such as immunotherapy or chemotherapy. This ADC, or antibody-drug conjugate, is the first approval of its kind. This ADC treatment is designed with two key elements. One part of the…
Watch HOPE Summit Videos
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
What Are Antibody-Drug Conjugates and How Do They Treat Lung Cancer?
Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and immunotherapy. Now, we are seeing the emergence of another class of lung cancer treatments called antibody-drug conjugates (ADCs), that are a combination of targeted therapy and chemotherapy.ADCs act like a “smart chemotherapy” that aim to deliver the drug compound directly to cancer cells, reducing harm to healthy tissue.As…
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
Integrative Oncology and Lung Cancer: Adding Complementary Therapy
What Is Integrative Oncology? Integrative oncology is the use of complementary therapies alongside conventional lung cancer treatments like chemotherapy, targeted therapy, surgery, or immunotherapy. Integrative oncology—also called integrative medicine—is an evidence-informed whole-body approach to health. It is often used to address symptoms and side effects caused by disease or treatment and improve overall quality of life. Specific examples of integrative oncology for lung cancer…
What Should Patients Know About Lung Cancer Surgery?
What Should Patients Know About Lung Cancer Surgery?
Surgery is a treatment option for early-stage lung cancer that involves removing all or part of a lung to treat a cancerous tumor. It is primarily an option for people with non-small cell lung cancer (NSCLC) staged at I, II, or IIIA. Surgery is rarely considered for tumors at stage IIIB or IV because those lung cancers have spread to other parts of the body. It is also rarely used to treat small cell lung cancer (SCLC) because SCLC is typically diagnosed at a later stage. Types of…
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
Conversations that Count: Transforming Lung Cancer Care Through Insight and Innovation
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center…
How Do We Treat Early-Stage NSCLC in 2025?
How Do We Treat Early-Stage NSCLC in 2025?
Roughly 20% of lung cancer is diagnosed as early-stage disease, and researchers have been working to improve treatment options for these patients—with significant success. Last September, as part of LUNGevity’s International Lung Cancer Survivorship Conference, we hosted a session on the progress in treating early-stage non-small cell lung cancer (NSCLC) with Dr. Jarushka Naidoo of Beaumont RCSI Cancer Centre in Ireland and Dr. Amy Moore of LUNGevity Foundation. In October,…
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Laughs for Lungs: Rasheed Marshall Combines Comedy With Cancer
Rasheed Marshall understands the secondhand effects of cancer well. First his mom, Joycelyn, was diagnosed with breast cancer in 1995. It came back in 2015 and eventually metastasized (spread) to her lungs. Soon after, his brother-in-law Romain was diagnosed with brain cancer. They both passed away the same week. “It was tough for the entire family when we learned mom’s cancer came back. She didn’t want to go through treatment again—which is why she didn’t tell us about it right away—so…
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
Staying Safe From Smoke, Pollution, and Dangerous Air Quality
On the West Coast, wildfires are taking human lives and destroying homes. On the East Coast, the devastating results of Hurricane Helene are leading to illegal open burning of debris and trash. Thousands of miles separate these fires, but the results are the same—dangerous particles are entering the air we breathe. LUNGevity spoke with Angela Hopper, an 11-year lung cancer survivor who spent 30 years working as an air quality specialist at the North Carolina Department of Environmental…
Have You Heard About Cancer Cachexia?
Have You Heard About Cancer Cachexia?
Cachexia is a complex condition that causes severe muscle and weight loss, physical inactivity, and metabolic disruptions such as fatigue, nausea, and loss of concentration. It's estimated that 50% of individuals with lung cancer experience cachexia at some point.Learn more about cachexia and how to recognize the symptoms.
Conversations that Count: Understanding the Complexities of Race and Health
Conversations that Count: Understanding the Complexities of Race and Health
The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In January, we welcomed Matthew McCurdy, MPH, co-founder and executive director of BLKHLTH, to speak on the complexities of race and…
Real-World Examples of Patient Involvement in Designing Clinical Trials
Real-World Examples of Patient Involvement in Designing Clinical Trials
Read time: 2 minutes.Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can…
Developing Clinical Trials that Account for the Realities of Patient Life
Developing Clinical Trials that Account for the Realities of Patient Life
Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients…
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Our Dream Was to Start a Family, but Lung Cancer Changed Everything
Read time: 6 minutes. After a few unimpressive encounters I experienced in real life, I tentatively returned to the Match dating app. That’s where I stumbled upon a very sweet, kind-hearted, nerdy, and compassionate man. Then I met Nate (Ha! Just joking). It was Nate. We bonded so quickly during which we identified our life goals. One goal was to have a family. Yes, we did the whole “let’s get ready” experience. We invested in a new SUV. We were eyeing new housing…